AstraZeneca has made public plans to discontinue a late-stage trial for heart disease drug Epanova to treat patients with mixed dyslipidaemia and expects a $100 million writedown to hit its core profit in the fourth quarter. The biopharma says the decision, which followed recommendations from an independent data monitoring committee, was due to low likelihood of Epanova’s benefit to patients with mixed dyslipidaemia. AstraZeneca added Epanova, which is already approved in the United States to reduce high levels of triglyceride, to its pipeline when it bought U.S.-based Omthera Pharmaceuticals in 2013 to build up its cardiovascular drug business. Learn More